P. Flynn

发表

Anti-tumor activity of CCI-779 in relapsed mantle cell lymphoma

P. Kurtin, S. Geyer, S. Ansell, 2009 .

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

J. Buckner, P. Brown, K. Ballman, 2007, Neuro-oncology.

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

M. Somerfield, K. Anderson, S. Jagannath, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

E. Perez, D. Visscher, J. Ingle, 2005, Clinical breast cancer.

Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations.

R. Branda, D. Arthur, P. Flynn, 1983, Blood.

Oral Clonidine in Postmenopausal Patients with Breast Cancer Experiencing Tamoxifen-Induced Hot Flashes: A University of Rochester Cancer Center Community Clinical Oncology Program Study

P. Flynn, K. Pandya, V. Dragalin, 2000, Annals of Internal Medicine.

Aggregation, chemotaxis, and chemiluminescence of canine granulocytes

P. Flynn, H. Redl, G. Schlag, 1983, Inflammation.

Ibuprofen inhibits granulocyte responses to inflammatory mediators

P. Flynn, G. Vercellotti, D. Weisdorf, 1984, Inflammation.

Synergy among agents inhibiting granulocyte aggregation

P. Flynn, H. Jacob, D. Hammerschmidt, 1982, Inflammation.

Chronic Myelogenous Leukemia: Development of Blast Crisis With Both Lymphoid and Myeloid Features

T. Lebien, P. Flynn, D. Weisdorf, 1983 .

Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy.

J. Hainsworth, A. Grothey, S. Sarkar, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.

J. Berlin, A. Grothey, F. Kabbinavar, 2009, The oncologist.

Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative br

H. Gómez, N. Robert, C. Geyer, 2016 .

Abstract S5-06: Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG S1202)

C. Moinpour, J. Unger, L. Fehrenbacher, 2017 .

Gemcitabine, 5‐fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma

S. Alberts, M. Mahoney, P. Flynn, 2005, Cancer.

Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer

E. Perez, K. Rowland, A. Dueck, 2013 .

M. Somerfield, N. Petrelli, T. Smith, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.

N. Foster, S. Dakhil, S. Alberts, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial.

E. Perez, S. Martino, D. Visscher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer

M. Somerfield, A. Benson, D. Haller, 2004 .

Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).

J. Hainsworth, A. Grothey, P. Flynn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

N. Petrelli, N. Wolmark, M. O’connell, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

M. Somerfield, E. Van Cutsem, A. Benson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines.

M. Somerfield, N. Petrelli, T. Smith, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.

K. Anderson, Nofisat Ismaila, S. Jagannath, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive‐stage small cell lung cancer, N0423

J. Jett, N. Foster, K. Rowland, 2010, Cancer.

Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.

E. Perez, P. Flynn, T. Fitch, 2012, Clinical breast cancer.

Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S

R. Robles, A. Grothey, F. Kabbinavar, 2005 .

Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.

M. Prados, J. Uhm, K. Hess, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

ASCO 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma: Guideline Summary.

M. Somerfield, K. Anderson, S. Jagannath, 2007, Journal of oncology practice.

The association between partner support and psychological distress among prostate cancer survivors in a nationwide study

C. Heckler, D. Spiegel, S. Mohile, 2015, Journal of Cancer Survivorship.

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

E. Perez, K. Rowland, W. Lingle, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Results from the BRiTE observational cohort study (OCS)

D. Sargent, J. Berlin, A. Grothey, 2008 .

Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE observational cohort study (OCS)

D. Sargent, J. Berlin, A. Grothey, 2008 .

Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8

C. Loprinzi, K. Rowland, S. Dakhil, 2010, Supportive Care in Cancer.

N0539 Phase II Trial of Fulvstrant and Bevacizumab in Patients with Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor: A North Central Cancer Treatment Group Trial.

E. Perez, J. Copland, K. Rowland, 2009 .

Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5.

C. Loprinzi, J. Kugler, K. Rowland, 2010 .

Translational correlates, including outcome for patients with ER-/PR-/HER2- (triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC)

M. Aubry, M. Aubry, W. Lingle, 2007 .

A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group.

K. Rowland, S. Dakhil, P. Flynn, 2007, Urology.

A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma

P. Novotny, J. Sloan, S. Dakhil, 2003, Cancer.

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma

G. Linette, J. Sosman, G. Schwartz, 2017, Journal of Cancer Research and Clinical Oncology.

A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study.

S. Mandrekar, N. Foster, M. Aubry, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52

S. Paik, N. Wolmark, S. Swain, 2017 .

Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group.

S. Ansell, S. Dakhil, S. Kaufmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease.

H. Balfour, P. Flynn, J. Kersey, 1986, Blood.

N0539 Phase Ii Trial of Fulvestrant and Bevacizumab in Patients with Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor: a North Central Cancer Treatment Group (now Alliance) Trial † Original Articles Annals of Oncology

E. Perez, K. Rowland, A. Dueck, 2022 .

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

J. Dipersio, C. Erlichman, P. Flynn, 2011, Annals of Hematology.

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study

T. Julian, C. Geyer, N. Wolmark, 2014, Breast Cancer Research and Treatment.

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.

M. Millward, H. Pitot, J. Picus, 2013, Clinical genitourinary cancer.

Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.

T. Habermann, S. Geyer, T. Witzig, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS)

J. Berlin, A. Grothey, F. Kabbinavar, 2008 .

An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Jesse S. Voss, B. Goh, R. Smallridge, 2020, Thyroid : official journal of the American Thyroid Association.

MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.

M. Millward, H. Pitot, J. Picus, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

J. Friedberg, P. Flynn, B. Holkova, 2018 .

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

Peter A Kaufman, James N Ingle, Edith A Perez, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study

D. Sargent, J. Berlin, A. Grothey, 2008 .

Granulated T cell lymphocytosis with neutropenia: malignant or benign chronic lymphoproliferative disorder?

D. Arthur, P. Flynn, R. Brunning, 1985, Blood.

Antithymocyte globulin treatment of severe aplastic anaemia

R. Branda, P. Flynn, H. Jacob, 1983, British journal of haematology.

N0337: Phase II study of capecitabine in combination with vinorelbine and trastuzumab for the first or second treatment of HER2+ metastatic breast cancer.

E. Perez, J. Kugler, P. Flynn, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Enzastaurin, a Protein Kinase C-β (PKCβ) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

J. Vose, K. Savage, D. Neuberg, 2005 .

Progress in reducing anticipatory nausea and vomiting: a study of community practice

P. Flynn, G. Morrow, J. Roscoe, 1997, Supportive Care in Cancer.

NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study.

J. Sarkaria, B. Scheithauer, J. Buckner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Iii Randomized Study of Postradiotherapy Chemotherapy with ␣-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-n؅- Cyclohexyl-n-nitrosurea, Vincristine (dfmo-pcv) versus Pcv for Glioblastoma Multiforme the Starting Dosage of Dfmo Was 3.0 G/m 2 P.o. Q8h for 14 Days before and after Treatm

Susan M. Chang, M. Prados, J. Uhm, 2022 .

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

G. Linette, J. Wolchok, J. Sosman, 2014, JAMA.

A Phase II NCCTG Study of Irinotecan and Docetaxel in Previously Treated Patients with Non-Small Cell Lung Cancer

J. Jett, S. Hillman, K. Rowland, 2006, Cancer investigation.

A randomized, placebo-controlled, double blind, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gem versus gem alone in patients with resected pancreas cancer with activating RAS mutations/survival and immunology analysis of the R1 subgroup.

F. Harrell, W. Fisher, A. Rosemurgy, 2012 .

Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.

S. Lipsitz, J. Kirkwood, A. Benson, 1996, American journal of clinical oncology.

Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).

G. Linette, J. Wolchok, J. Sosman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors

C. Heckler, S. Mohile, P. Flynn, 2014, Supportive Care in Cancer.

National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention Trial.

P. Flynn, R. Zera, R. Dalton, 1993, Minnesota medicine.

Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine.

T. Rummans, T. Shanafelt, J. Sloan, 2005, Journal of palliative medicine.

A Phase II Trial of Docetaxel and Carboplatin as First-Line Chemotherapy for Metastatic Breast Cancer: NCCTG Study N9932

E. Perez, J. Ingle, V. Suman, 2005, Oncology.

National Cancer Institute--supported cancer chemoprevention research: coming of age.

W. McCaskill-Stevens, S. Lippman, E. Hawk, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.

J. Uhm, J. Buckner, E. Galanis, 2010 .

Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline.

Bruce D Minsky, M. Somerfield, N. Petrelli, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1.

P. Novotny, J. Sloan, C. Loprinzi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of lamotrigine in the management of chemotherapy‐induced peripheral neuropathy

G. Y. Wong, P. Novotny, G. Wong, 2008, Cancer.

Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.

M. Prados, K. Hess, J. Bruner, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase III Randomized Study of Postradiotherapy Chemotherapy with Combination-Difluoromethylornithine-PCV versus PCV for Anaplastic Gliomas 1

M. Prados, K. Hess, J. Bruner, 2003 .

Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer

R. Ozols, P. O'dwyer, P. Flynn, 2004, Cancer Chemotherapy and Pharmacology.

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

J. Uhm, J. Buckner, E. Galanis, 2013, Clinical Cancer Research.

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Caterina Giannini, Jan C Buckner, B. Scheithauer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis

R. B. Jenkins, B. Scheithauer, J. Buckner, 2011, Journal of Neuro-Oncology.

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.

S. Paik, J. Costantino, C. Geyer, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study

Peter A. Jones, P. Laird, D. Weisenberger, 2017, Oncotarget.

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.

J. Vose, A. LaCasce, S. de Vos, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.

J. Sarkaria, J. Uhm, J. Buckner, 2015, Neuro-oncology.

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

R. Fonseca, S. Dakhil, S. Kaufmann, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study

H. Pitot, J. Picus, C. Erlichman, 2015, Cancer Chemotherapy and Pharmacology.

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL.

J. Friedberg, P. Flynn, A. Forero-Torres, 2017, Blood.

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

David Cella, Lynne Wagner, Christopher H Crane, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.

A. Grothey, F. Kabbinavar, P. Flynn, 2012, European journal of cancer.

Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

C. James, J. Uhm, B. Scheithauer, 2011, International journal of radiation oncology, biology, physics.

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

A. Khorana, P. Philip, C. Fenoglio-Preiser, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study.

D. Moore, P. Flynn, J. Atkins, 2003, Journal of pain and symptom management.

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

J. Hainsworth, R. Herbst, L. Hart, 2011, The Lancet.

Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients.

C. Heckler, S. Dakhil, P. Flynn, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Severe thrombocytopenia in Epstein-Barr virus-induced mononucleosis.

P. Flynn, W. Henle, G. Henle, 1989, The Western journal of medicine.

Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients

C. Heckler, S. Dakhil, P. Flynn, 2012, Supportive Care in Cancer.

Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mFOLFOX6 and bevacizumab (Bev) for patients (pts) with stage II/ III rectal cancer receiving pre-operative chemoradiation.

P. Catalano, A. Benson, N. Petrelli, 2016 .

Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma

K. Kolibaba, P. Flynn, L. Garbo, 2009, Investigational New Drugs.

Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma

D. Moore, S. Ansell, K. Rowland, 2008, Cancer.

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

C. Moinpour, J. Unger, L. Fehrenbacher, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement.

J. Meyerhardt, A. Benson, N. Petrelli, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204).

P. Catalano, N. Petrelli, J. Sloan, 2019, The oncologist.

Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.

S. Lippman, P. Philip, C. Moinpour, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of 5‐HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings

R. Stern, P. Flynn, G. Morrow, 1999 .

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)

J. Sarkaria, J. Buckner, P. Brown, 2019, Journal of Neuro-Oncology.

CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design.

K. Aldape, P. Brown, M. J. van den Bent, 2020, Neuro-oncology.

A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer

F. Harrell, T. Bekaii-Saab, W. Fisher, 2021, Journal of pancreatic cancer.

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

R. Smallridge, C. Erlichman, V. Suman, 2014, The Journal of clinical endocrinology and metabolism.

A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas

R. Hellman, D. Neuberg, P. Flynn, 1998, Journal of Neuro-Oncology.

A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity.

L. Gordon, J. Winter, T. Habermann, 1999, Blood.

THERAPEUTIC RAMIFICATIONS OF THE INTERACTION OF COMPLEMENT, GRANULOCYTES, AND PLATELETS IN THE PRODUCTION OF ACUTE LUNG INJURY *

P. Flynn, G. Vercellotti, D. Weisdorf, 1982, Annals of the New York Academy of Sciences.

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

P. Philip, M. Mahoney, H. Pitot, 2012, Cancer.

Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).

J. Hainsworth, A. Grothey, P. Flynn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program.

P. Flynn, P. Andrews, R. Raubertas, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

H. Gómez, N. Robert, C. Geyer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer

C. Geyer, N. Wolmark, S. Swain, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422).

N. Foster, A. Adjei, K. Rowland, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of cetuximab and radiation in elderly and / or poor performance status patients with locally advanced non-small-cell lung cancer ( N 0422 )

N. Foster, A. Adjei, K. Rowland, 2010 .

A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.

Danielle M. Enserro, A. Secord, P. Sabbatini, 2018 .

A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study.

J. Herman, S. Baylin, N. Ahuja, 2013 .

Group psychotherapy for recently diagnosed breast cancer patients: a multicenter feasibility study

C. Classen, D. Spiegel, P. Flynn, 1999, Psycho-oncology.

Effects of Group Therapy on Women with Primary Breast Cancer

C. Classen, D. Spiegel, P. Flynn, 1996 .

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

J. Sarkaria, J. Buckner, B. Erickson, 2018, Cancer.

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

B. Goh, R. Smallridge, Hui Tang, 2010, The Lancet. Oncology.

Cancer Therapy : Clinical Phase II StudyofBevacizumab inCombinationwithSorafenib in Recurrent Glioblastoma ( N 0776 ) : A North Central Cancer Treatment Group Trial

J. Uhm, J. Buckner, E. Galanis, 2013 .

Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106.

E. Shaw, R. Zon, G. Lesser, 2015, The Journal of community and supportive oncology.

Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial

T. Sweeney, P. Flynn, K. Pandya, 2005, The Lancet.

Hot flashes severity, complementary and alternative medicine use, and self-rated health in women with breast cancer.

C. Heckler, S. Mohile, P. Flynn, 2014, Explore.

Ibuprofen inhibits granulocyte responses to inflammatory mediators. A proposed mechanism for reduction of experimental myocardial infarct size.

P. Flynn, G. Vercellotti, D. Weisdorf, 1984, Inflammation.

CTNI-29. CODEL: PHASE III TRIAL OF RT ALONE, RT PLUS TMZ, OR TMZ ALONE FOR NEWLY-DIAGNOSED, 1p/19q CODELETED ANAPLASTIC OLIGODENDROGLIOMA. ANALYSIS FROM THE INITIAL STUDY DESIGN. (NCCTG N0577, ALLIANCE)

K. Aldape, P. Brown, M. Weller, 2020 .

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

B. Melichar, G. Deplanque, P. Flynn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study.

E. Perez, R. Gelber, L. Hartmann, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study

J. Berlin, A. Grothey, F. Kabbinavar, 2010, Oncology.

Association of coping style, pain, age and depression with fatigue in women with primary breast cancer

C. Classen, D. Spiegel, P. Flynn, 2006, Psycho-oncology.

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.

B. Melichar, G. Deplanque, P. Flynn, 2015 .

Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.

A. Benson, J. Sparano, C. Loprinzi, 2021 .

Analysis of paired glioma tissues from initial diagnosis and recurrence in patients enrolled on NCCTG clinical trials: De-differentiation and association with survival.

B. Scheithauer, J. Buckner, K. Ballman, 2006, Journal of Clinical Oncology.

Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial.

E. Raymond, B. Melichar, G. Deplanque, 2013 .

A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

C. Erlichman, P. Flynn, B. Laplant, 2015, Leukemia & lymphoma.

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab

C. Geyer, N. Wolmark, P. Ganz, 2021, NPJ breast cancer.

2000 U pdate o f A merican S ociety o f C linical O ncology Colorectal C ancer S urveillance G uidelines

Thomas J. Smith, M. Somerfield, N. Petrelli, 2000 .

Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)

D. Moore, N. Foster, K. Rowland, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A preliminary report of a double blind placebo controlled trial of gabapentin for control of hot flashes in women with breast cancer. A University of Rochester Cancer Center CCOP study.

J. Roscoe, P. Flynn, K. Pandya, 2004, Journal of Clinical Oncology.

Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials

J. Buckner, P. Flynn, M. Kosel, 2008 .

Group psychotherapy for recently diagnosed breast cancer patients: a multicenter feasibility study

C. Classen, D. Spiegel, P. Flynn, 1999, Psycho-oncology.

Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma.

D. Moore, N. Foster, S. Alberts, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

3049 POSTER Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT)

J. Hainsworth, A. Grothey, J. Yi, 2007 .

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

J. Uhm, J. Buckner, E. Galanis, 2013, Clinical Cancer Research.

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL.

J. Friedberg, P. Flynn, A. Forero-Torres, 2017, Blood.

Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver

J. Donohue, J. Kugler, S. Alberts, 2008 .

Aggregation, chemotaxis, and chemiluminescence of canine granulocytes. Studies utilizing improved cell preparation techniques.

P. Flynn, H. Redl, G. Schlag, 1983, Inflammation.

NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).

M. Buyse, T. Julian, S. Paik, 2012 .

Comparison of survival endpoints in glioblastoma patients receiving or not receiving enzyme-inducing anticonvulsants in NCCTG Trials.

J. Uhm, B. Scheithauer, J. O'fallon, 2004, Journal of Clinical Oncology.